{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:46:57Z","timestamp":1791841617617,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.obpill.2026.100331","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:15:52Z","timestamp":1788390952000},"page":"100331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2403-4745","authenticated-orcid":false,"given":"Farah","family":"Kalagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Algindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100331_bib1","series-title":"Handbook of healthcare in the Arab world","first-page":"1155","article-title":"Overweight and obesity among saudi children: prevalence, lifestyle factors, and health impacts","author":"Aljaadi","year":"2021"},{"key":"10.1016\/j.obpill.2026.100331_bib2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.15537\/1658-3175.2970","article-title":"Obesity in Saudi Arabia","volume":"26","author":"Al-Nozha","year":"2005","journal-title":"Saudi Med J"},{"key":"10.1016\/j.obpill.2026.100331_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4274\/Jcrpe.898","article-title":"The effect of parental socioeconomic class on children's body mass indices","volume":"5","author":"Alwan \u0130brahim","year":"2013","journal-title":"Jcrpe"},{"key":"10.1016\/j.obpill.2026.100331_bib4","series-title":"Chronic disease\u2014overweight and obesity","year":"2025"},{"key":"10.1016\/j.obpill.2026.100331_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1542\/9781610027052-part01-clinical","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","author":"Hampl","year":"2023","journal-title":"Pediatric Collections: Adolescent Health Part 1: Promoting Wellness"},{"key":"10.1016\/j.obpill.2026.100331_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/chi.2018.0066","article-title":"Psychological factors and cardiovascular disease risk factors as mediators of the relationship between overweight\/obesity and cognitive function among school children in Kuala Lumpur, Malaysia","volume":"15","author":"Tung","year":"2019","journal-title":"Child Obes"},{"key":"10.1016\/j.obpill.2026.100331_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jsams.2017.09.019","article-title":"Physical fitness and psychological health in overweight\/obese children: a cross-sectional study from the ActiveBrains project","volume":"21","author":"Rodriguez-Ayllon","year":"2018","journal-title":"J Sci Med Sport"},{"key":"10.1016\/j.obpill.2026.100331_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/07380577.2013.784839","article-title":"Childhood obesity: effects on children's participation, mental health, and psychosocial development","volume":"27","author":"Pizzi","year":"2013","journal-title":"Occup Ther Health Care"},{"key":"10.1016\/j.obpill.2026.100331_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41366-018-0230-y","article-title":"Interventions for treating children and adolescents with overweight and obesity: an overview of cochrane reviews","volume":"42","author":"Ells","year":"2018","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2026.100331_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jc.2016-2573","article-title":"Pediatric obesity\u2014assessment, treatment, and prevention: an endocrine society clinical practice guideline","volume":"102","author":"Styne","year":"2017","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2026.100331_bib11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3224","article-title":"Metabolic and bariatric surgery for pediatric patients with severe obesity","volume":"144","author":"Bolling","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.obpill.2026.100331_bib12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/jamapediatrics.2018.3030","article-title":"National trends in the use of metabolic and bariatric surgery among pediatric patients with severe obesity","volume":"172","author":"Griggs","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.obpill.2026.100331_bib13","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1210\/clinem\/dgad155","article-title":"Long-term outcomes following adolescent metabolic and bariatric surgery","volume":"108","author":"Beamish","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2026.100331_bib14","series-title":"FDA approves weight management drug for patients aged 12 and older","year":"2020"},{"key":"10.1016\/j.obpill.2026.100331_bib15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100331_bib16","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100331_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and efficacy of glucagon-like Peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis","volume":"236","author":"Ryan","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.obpill.2026.100331_bib18","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/children12111427","article-title":"Beyond weight loss: optimizing GLP-1 receptor agonist use in children","volume":"12","author":"Zaitoon","year":"2025","journal-title":"Children"},{"key":"10.1016\/j.obpill.2026.100331_bib19","series-title":"Adolescent health","year":"2021"},{"key":"10.1016\/j.obpill.2026.100331_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.756","article-title":"Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP\u20101, GIP receptor agonists, and dual agonists","volume":"10","author":"Garvey","year":"2024","journal-title":"Obesity Science & Practice"},{"key":"10.1016\/j.obpill.2026.100331_bib21","doi-asserted-by":"crossref","DOI":"10.46743\/2160-3715\/2021.5010","article-title":"Reflexive thematic analysis for applied qualitative health research","author":"Campbell","year":"2021","journal-title":"TQR"},{"key":"10.1016\/j.obpill.2026.100331_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human participants","volume":"333","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2026.100331_bib23","article-title":"Effects of glucagon-like Peptide-1 receptor agonists after treatment withdrawal: a systematic review and meta-analysis","author":"Zhou","year":"2025","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.obpill.2026.100331_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.70127","article-title":"Correlates of obesity medication use in paediatric weight management programmes: a POWER consortium analysis","volume":"21","author":"Christison","year":"2026","journal-title":"Pediatric Obesity"},{"key":"10.1016\/j.obpill.2026.100331_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jss.2024.05.045","article-title":"Practice patterns of glucagon-like Peptide-1 agonist use among pediatric bariatric surgeons: a national survey","volume":"301","author":"Kochis","year":"2024","journal-title":"J Surg Res"},{"key":"10.1016\/j.obpill.2026.100331_bib26","series-title":"SAUDI guideline on the PRVENTION and management of overweight and obesity","year":"2022"},{"key":"10.1016\/j.obpill.2026.100331_bib27","series-title":"The STROBE reporting checklist","author":"Elm","year":"2025"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:08:58Z","timestamp":1791839338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S2667368126000872"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100331","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100331"}}